- Home
- BYRN vs CTNM Comparison
BYRN vs CTNM Comparison
Compare BYRN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BYRN | CTNM |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.2M | 416.1M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | BYRN | CTNM |
|---|---|---|
| Price | $17.30 | $12.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $41.50 | $18.60 |
| AVG Volume (30 Days) | ★ 486.9K | 252.8K |
| Earning Date | 02-06-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 543.53 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $110,853,000.00 | N/A |
| Revenue This Year | $40.07 | N/A |
| Revenue Next Year | $20.31 | N/A |
| P/E Ratio | $26.56 | ★ N/A |
| Revenue Growth | ★ 50.99 | N/A |
| 52 Week Low | $13.68 | $3.35 |
| 52 Week High | $34.78 | $13.57 |
Technical Indicators
Market Signals| Indicator | BYRN | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 59.30 |
| Support Level | $16.31 | $8.92 |
| Resistance Level | $17.79 | $11.90 |
| Average True Range (ATR) | 0.86 | 0.92 |
| MACD | 0.08 | 0.16 |
| Stochastic Oscillator | 59.46 | 84.13 |
Price Performance
Historical ComparisonAbout BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.